Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease

Brain

Volumn 131, Issue 11, 2008, Pages 2851-2859

  Leoni, Valerio ^a   Mariotti, Caterina ^a   Tabrizi, Sarah J ^b   Valenza, Marta ^c   Wild, Edward J ^b   Henley, Susie M D ^b   Hobbs, Nicola Z ^b   Mandelli, Maria Luisa ^a,d   Grisoli, Marina ^a   Björkhem, Ingemar ^e   Cattaneo, Elena ^c   Di Donato, Stefano ^a,b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

^d POLITECNICO DI MILANO   (Italy)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

24S hydroxycholesterol; Biomarker; Caudate volume; Gas chromatography mass spectrometry; MRI; Oxysterol

Indexed keywords

24 HYDROXYCHOLESTEROL; BIOLOGICAL MARKER; CHOLESTEROL DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN SIZE; CAUDATE NUCLEUS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; ITALY; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SYMPTOMATOLOGY; UNITED KINGDOM;

ADULT; BIOLOGICAL MARKERS; BRAIN MAPPING; CAUDATE NUCLEUS; CHOLESTEROL; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HUNTINGTON DISEASE; HYDROXYCHOLESTEROLS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 55749085638     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn212     Document Type: Article

References (34)

1. Aylward EH. Change in MRI striatal volumes as a biomarker in preclinical Huntington disease. Brain Res Bull 2007; 72: 152-8.
2. Aylward EH, Sparks BF, Field BA, Yallapragada V, Shpritz OD, Resenblatt A, et al. Onset and rate of striatal atrophy in preclinical Huntington's disease. Neurology 2004; 63: 66-72.
3. Björkhem I. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J Intern Med 2006a; 260: 493-508.
4. Björkhem I, Heverin M, Leoni V, Meaney S, Diczfalusy U. Oxysterols and Alzheimer's disease. Acta Neurol Scand Suppl 2006b; 185: 43-9.
5. Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscl Thromb Vasc Biol 2004; 24: 806-15.
6. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 2005; 6: 919-30.
7. Cohn JS, McNamara JR, Schaefer EJ. Lipoprotein cholesterol concentrations in the plasma of human subjects measured in the fed and fasted states. Clin Chem 1988; 34: 2456-9.
8. Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Bjorkqist M, Petersen A, et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteom Res 2007; 6: 2833-40.
9. Dietschy JM, Turley SD. Brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004; 45: 1375-97.
10. Dzeletovic S, Breuer O, Lund E, Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal Biochem 1995; 225: 73-80.
11. Gellera C, Meoni C, Castellotti B, Zappacosta B, Girotti F, Taroni F, et al. Errors in Huntington disease diagnostic test caused by trinucleotide deletion in the IT15 gene. Am J Hum Genet 1996; 59: 475-77.
12. Graham RK, Deng Y, Slow EJ, Brendan H, Nagat B, Ge L, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006; 125: 1179-91.
13. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-83.
14. Huntington Study Group. The unified Huntington's disease rating scale: reliability and consistency. Mov Dis 1996; 11: 136-42.
15. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. Neurology 1994; 44: 1533-6.
16. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. International Huntington's disease collaborative group. 2004. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004; 66: 81.
17. Leoni V, Masterman T, Diczfalusy U, De Luca G, Hillert J, Björkhem I. Changes in human plasma levels of 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci Lett 2002; 331: 163-6.
18. Lund EG, Guileyardo JM, Russel DW. cDNA cloning of cholesterol 24-hydroxylase, a mediator of the cholesterol homeostasis in the brain. Proc Natl Acad Sci USA 1999; 96: 7238-43.
19. Lund EG, Xie C, Koth T, Turley SD, Dietschy GM, Russel DW. Knockout of the cholesterol-24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 2003; 278: 22980-8.
20. Lütjohann D, Breuer O, Ahlborg G, Nennesmo I, Siden Å, Diczfalusy U, et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA 1996; 93: 9799-804.
21. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, et al. Rate of functional decline in Huntington's disease. Neurology 2000; 54: 452-8.
22. Pfriger FW. Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci 2003; 60: 1158-71.
23. Reading SAJ, Dziorny AC, Peroutka LA, Schreiber M, Gourley LM, Yallapragada V, et al. Functional brain changes in presymptomatic Huntington's disease. Ann Neurol 2004; 55: 879-83.
24. Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationships to cognition. Neurology 2005; 65: 745-7.
25. Rosas HD, Koroshetz WJ, Chen Y, Skeuse C, Vangel M, Cudkowicz ME, et al. Evidence for a more widespread cerebral pathology in early HD. Neurology 2003; 60: 1615-20.
26. Taroni F, Di Donato S. Pathways to motor incoordination: the inherited ataxias. Nat Rev Neurosci 2004; 5: 641-55.
27. Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005; 4: 32-41.
28. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N. Automated anatomical labelling of activations in spm using a macroscopic anatomical parcellation of the MNI MRI single subject brain. NeuroImage 2002; 15: 273-89.
29. Valenza M, Carroll JB, Leoni V, Bertram L, Björkhem I, Singharaja SS, et al. Cholesterol biosynthetic pathway is impaired in YAC128 mice and is related to huntingtin expression. Hum Mol Genet. 2007a; 16: 2187-98.
30. Valenza M, Leoni V, Tarditi A, Mariotti C, Bjorkhem I, Di Donato S, et al. Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2007b; 28: 133-42.
31. Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 2005; 25: 9932-9.
32. Vonsattel JPG, DiFiglia M. Huntington disease. J Neuropath Exp Neurol 1998; 57: 369-84.
33. Walker FO. Huntington's disease. Lancet 2007; 369: 218-28.
34. Whitwell JL, Crum WR, Watt HC, Fox NC. Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. Am J Neuroradiol 2001; 22: 1483-9.